Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia

Inclusion Criteria:

* Patients with chronic phase CML who lost response to the second line of treatment with tyrosine-kinase inhibitor (TKI) with indication for bone marrow transplantation.
* Accelerated phase patients who are candidates for bone marrow transplantation.
* Patient with CML in blast crisis.
* Patient aged between 2 and 59 years.
* patient should have recovered from the toxicity related to previous treatment of cytotoxic agents received within 4 weeks before starting treatment in this protocol, except for cytopenias resulting from persistent disease and alopecia, or non-haematological toxicities grades 1 and 2

Exclusion Criteria:

* Zubrod performance scale ≥ 2
* Renal impairment: Serum creatinine\> 2mg / dL for adults and\> 2mg / dL or\> 2 times the upper limit of normality for age (whichever is less) for children.
* Impaired hepatic function, defined as: total bilirubin\> 2 mg / dL and alanine aminotransferase (ALT) 2.5 times upper limit of normal for age (unless Gilbert's disease or abnormal liver function due to primary disease).
* Pulmonary symptoms with pulse oximetry \<92%.
* Congestive Heart Failure Classification New York Heart Association\> III
* Positive serological test for pregnancy within two weeks prior to enrollment in women of childbearing potential (non-fertile age defined as pre-menarche, post-menopausal over one year, or surgically sterilized).
* Positive serology for human immunodeficiency virus (HIV).
* Have undergone investigational therapies in four weeks prior to treatment begin under this protocol.
* Congestive heart failure \< 6 months prior to screening.
* Unstable angina \< 6 months before screening.
* Myocardial infarction \< 6 months prior to selection.
* Non-signing of the informed consent.